+1-888-308-5802     
Industry Categories News Contact Us

Glenmark & Harbour BioMed team up, develop cancer antibodies in China

Author : Ojaswita Kutepatil | Published Date : 2018-08-08 

Mumbai-based Glenmark Pharmaceuticals has reportedly announced an exclusive license agreement with China-based Harbour BioMed. The deal, worth more than $120 million, showcases China’s willingness to transform healthcare by encouraging innovation.

Sources cite that the agreement aims at developing, producing & commercializing Glenmark’s GBR 1302 drug for the greater China region where the prevalence of certain HER2 positive cancer cases generates a clinical need.

A press release by Glenmark Pharma states that the GBR 1302 is a part of Glenmark’s patented BEAT platform and is a bispecific antibody that targets CD3 & HER2. It is utilized for the treatment of HER2 positive cancers. The drug is reportedly undergoing enrollment in the U.S. & Germany, and works by stimulating the immune system to fight against the HER2 overexpressing tumor cells.

The company would receive an upfront payment and payments on achieving certain development level, commercial & regulatory milestones, tiered royalties from Harbour BioMed on product sales.

Glenmark Chairman and MD, Glenn Saldanha expressed his delight about establishing this strategic relationship with Harbour BioMed whose extensive local experience will aid Glenmark in discovering, developing & innovating drugs for certain unfulfilled medical needs.

Harbour BioMed Founder & CEO, Dr. Jingsong Wang stated that this partnership aligns with their plan of leveraging company’s expertise in clinical development by in-licensing innovative clinical-stage products. He further added that the GBR 1302 compliments their internal portfolio of innovative antibody therapeutics.

Glenmark President and Chief Scientific Officer, Kurt Stoeckli stated that both companies follow the same principles and possess a common vision of developing highly effective & precise medicines to help cancer patients. He added that they look forward to achieving this goal together.

Post the announcement, Glenmark Pharma started trading 0.91% higher at about Rs. 602 per share, cite trusted sources.

About Author

Ojaswita Kutepatil

Ojaswita Kutepatil

Ojaswita Kutepatil, a mechanical engineer by qualification, worked as a BDE and Technical Engineer before switching her profession to content writing. Currently, she works at AlgosOnline. as an Content writer, where she pens down write-ups pertaining to the market research industry. Crafting, reading, and music are some of her other areas of interest.

She can be contacted at- [email protected] | https://twitter.com/ojaswita_k

Related News

NextDC invests $2.25 billion to build data centers in Australia

Published Date: 2018-09-02         Author: Ojaswita Kutepatil

Leading data center operator NextDC has declared plans to spend $2.25 billion on sites in Melbourne, Perth, and Sydney. The new sites will be developed into data centers for the likes of drones, nanotechnology and precision medicine. The purchase of the new north shore site has been funded by a r... Read More

Facebook pledges to run data centers on 100% renewable energy by 2020

Published Date: 2018-08-30         Author: Ojaswita Kutepatil

As a part of its pledge to combat climate change, Facebook has recently announced that it will be reducing its greenhouse gas emissions by 75% and will power its global operations with 100% renewable energy by 2020. According to sources familiar with the matter, the social-media behemoth has sign... Read More

Snam signs MOU with China’s SGID, focuses on low-emission economy

Published Date: 2018-08-29         Author: Ojaswita Kutepatil

In a bid to explore better opportunities of future cooperation in infrastructure & new technologies for a low-emission economy, the Italian transmission system operator (TSO) Snam has inked a Memorandum of Understanding (MoU) with China’s State Grid International Development Company (SGID)... Read More

© 2018 Fractovia. All Rights Reserved